文献速递肝病消化道肿瘤与早癌

美国肝细胞癌患者治疗延迟的种族、民族及社会经济差异

Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay Among Patients With Hepatocellular Carcinoma in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-04

基于监测、流行病学和最终结果-医疗保险数据库纳入2001至2015年确诊的8450例肝细胞癌患者,1205例(14.3%)在确诊12个月内接受治疗者出现治疗延迟;黑人患者和高贫困社区居住者治疗延迟的比值比更高,治疗延迟与更差的总生存独立相关。

要点

  • 8450例中14.3%出现治疗延迟,手术切除者延迟比例6.8%,肝移植者21.6%。
  • 黑人患者较高贫困社区居住者治疗延迟的比值比分别为1.96和1.55。
  • 治疗延迟与更差生存独立相关(风险比1.15,95%CI 1.05-1.25)。

核心结论

  • 近七分之一肝细胞癌患者经历治疗延迟,黑人患者和高贫困社区居住者治疗延迟的比值比更高,治疗延迟与更差生存相关。

研究设计与样本

  • 使用监测、流行病学和最终结果-医疗保险数据库识别2001至2015年确诊的肝细胞癌患者,纳入8450例在确诊12个月内接受治疗者。

主要发现

  • 1205例(14.3%)出现治疗延迟,延迟比例从手术切除者的6.8%到肝移植者的21.6%。
  • 黑人患者较白人患者治疗延迟的比值比为1.96(95%CI 1.21-3.15)。
  • 高贫困社区居住者较低贫困社区居住者治疗延迟的比值比为1.55(95%CI 1.25-1.92)。
  • 治疗延迟与更差总生存独立相关(风险比1.15,95%CI 1.05-1.25)。

关键数值与推荐

  • 治疗延迟定义为确诊后超过3个月接受肝细胞癌导向治疗。
  • 采用多因素logistic回归分析治疗延迟相关因素,采用5个月landmark的Cox比例风险回归分析治疗延迟与总生存的关联。

临床怎么用

  • 原文结论强调需要干预以改善治疗时间,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Failures have been reported across the cancer care continuum in patients with hepatocellular carcinoma (HCC); however, the impact of treatment delays on outcomes has not been well-characterized. We described the prevalence of treatment delays in a racially and ethnically diverse cohort of patients and its association with overall survival. METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified patients diagnosed with HCC between 2001 and 2015. We performed multivariable logistic regression analysis to identify factors associated with treatment delay (ie, receipt of HCC-directed therapy >3 months after diagnosis). Cox proportional hazards regression analysis with a 5-month landmark was used to characterize the association between treatment delay and overall survival, accounting for immortal time bias. RESULTS: Of 8450 patients with treatment within 12 months of HCC diagnosis, 1205 (14.3%) experienced treatment delays. The proportion with treatment delays ranged from 6.8% of patients undergoing surgical resection to 21.6% of those undergoing liver transplantation. In multivariable analysis, Black patients (odds ratio, 1.96; 95% confidence interval [CI], 1.21-3.15) and those living in high poverty neighborhoods (odds ratio, 1.55; 95% CI, 1.25-1.92) were more likely to experience treatment delays than white patients and those living in low poverty neighborhoods, respectively. Treatment delay was independently associated with worse survival (hazard ratio 1.15, 95% CI, 1.05-1.25). CONCLUSIONS: Nearly 1 in 7 patients with HCC experience treatment delays, with higher odds in Black patients and those living in high poverty neighborhoods. Treatment delays are associated with worse survival, highlighting a need for interventions to improve time-to-treatment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wagle NS, Park S, Washburn D, et al. Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay Among Patients With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2022. PMID: 35933076. doi:10.1016/j.cgh.2022.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。